- Open
- 0.23
- High
- 0.23
- Low
- 0.22
- Close
- 0.23
- Change
- -0.01 (-2.22%)
- Volume
- 22,919,260
| 22 Oct 2026 | 07:00:03 | Launch of US Kidney Care National Plan |
| 22 Oct 2026 | 07:00:03 | PTRA test to be used in Kidney Transplant Tx Study |
| 21 Oct 2026 | 13:35:25 | Holding(s) in Company |
| 15 Oct 2026 | 11:39:08 | Holding(s) in Company |
| 15 Oct 2026 | 11:33:23 | Holding(s) in Company |
| 20 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 7 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Verici DX PLC is a diagnostics company focused on improving outcomes for kidney transplant patients through a suite of proprietary tests. Utilizing artificial intelligence-assisted transcriptomic analysis, Verici DX develops RNA signatures that assess immune responses and biological pathways critical for predicting transplant risks, including injury, rejection, and graft failure. The company serves healthcare providers in the kidney transplant sector, primarily in the United States and Europe, addressing unmet needs for personalized diagnostics and tailored immunosuppressive therapies throughout the transplant journey.
Lord Stevens of Ludgate has interests in this issuer
| 22 Oct 2026 | 07:00:03 | Launch of US Kidney Care National Plan |
| 22 Oct 2026 | 07:00:03 | PTRA test to be used in Kidney Transplant Tx Study |
| 21 Oct 2026 | 13:35:25 | Holding(s) in Company |
| 15 Oct 2026 | 11:39:08 | Holding(s) in Company |
| 15 Oct 2026 | 11:33:23 | Holding(s) in Company |
| 20 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 7 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Verici DX PLC is a diagnostics company focused on improving outcomes for kidney transplant patients through a suite of proprietary tests. Utilizing artificial intelligence-assisted transcriptomic analysis, Verici DX develops RNA signatures that assess immune responses and biological pathways critical for predicting transplant risks, including injury, rejection, and graft failure. The company serves healthcare providers in the kidney transplant sector, primarily in the United States and Europe, addressing unmet needs for personalized diagnostics and tailored immunosuppressive therapies throughout the transplant journey.
Lord Stevens of Ludgate has interests in this issuer
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £41m | -0.3% | |
| £24m | +0.4% | |
| £17m | +1.2% | |
VRCIVerici DX PLC | £9m | -0.7% |
| £5m | -0.3% | |
| £4m | -0.4% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £41m | -0.3% | |
| £24m | +0.4% | |
| £17m | +1.2% | |
VRCIVerici DX PLC | £9m | -0.7% |
| £5m | -0.3% | |
| £4m | -0.4% |